Am J Perinatol 2009; 26(5): 373-377
DOI: 10.1055/s-0028-1110089
© Thieme Medical Publishers

The Fetal Heart Monitor Tracing in Pregnancies Complicated by Fetal Thyrotoxicosis

Craig V. Towers1 , Steven Thomas1 , Ralph M. Steiger1
  • 1Long Beach Memorial Women's Hospital, Long Beach, California
Further Information

Publication History

Publication Date:
09 December 2008 (online)

ABSTRACT

Fetal tachycardia caused by the transplacental passage of thyroid stimulating immunoglobulin is well established, but very little information exists regarding the fetal heart rate appearance of this form of tachycardia. Two cases of fetal tachycardia are described in pregnancies complicated by fetal thyrotoxicosis where maternal thyroid history was unknown at the time of testing. For each pregnancy, the fetal heart monitor tracing is depicted and described. In both cases, the initial fetal heart rate pattern demonstrated a sustained baseline of 170 to 180 beats per minute with moderate variability that exhibited accelerations with a lack of decelerations. The tracings were essentially normal except for the baseline rate. When reviewing the differential for fetal tachycardia presenting in the antenatal period, this pattern is unique to fetal thyrotoxicosis, especially if the mother is afebrile and there is no history of medication usage that could explain this presentation.

REFERENCES

  • 1 Srisupundit K, Sirichotiyakul S, Tongprasert F, Luewan S, Tongsong T. Fetal therapy in fetal thyrotoxicosis: a case report.  Fetal Diagn Ther. 2008;  23 114-116
  • 2 Nachum Z, Rakover Y, Weiner E, Shalev E. Grave's disease in pregnancy: prospective evaluation of a selective invasive treatment protocol.  Am J Obstet Gynecol. 2003;  189 159-165
  • 3 Peleg D, Cada S, Peleg A, Ben-Ami M. The relationship between maternal serum thyroid-stimulation immunoglobulin and fetal and neonatal thyrotoxicosis.  Obstet Gynecol. 2002;  99 1040-1043
  • 4 Duncombe G J, Dickinson J E. Fetal thyrotoxicosis after maternal thyroidectomy.  Aust N Z J Obstet Gynaecol. 2001;  41 224-227
  • 5 Volumenie J L, Polak M, Guibourdenche J et al.. Management of fetal thyroid goiters: a report of 11 cases in a single perinatal unit.  Prenat Diagn. 2000;  20 799-806
  • 6 Ting M K, Hsu B R, Huang Y Y, Lin J D, Chen T C. Recurrent fetal thyrotoxicosis in a woman with Grave's disease: case report.  Changgeng Yi Xue Za Zhi. 1999;  22 492-497
  • 7 Heckel S, Favre R, Schlienger J L, Soskin P. Diagnosis and successful in utero treatment of a fetal goitrous hyperthyroidism caused by maternal Grave's disease.  Fetal Diagn Ther. 1997;  12 54-58
  • 8 Treadwell M C, Sherer D M, Sacks A J, Ghezzi F, Romero R. Successful treatment of recurrent non-immune hydrops secondary to fetal hyperthyroidism.  Obstet Gynecol. 1996;  87 838-840
  • 9 Hadi H A, Strickland D. Prenatal diagnosis and management of fetal goiter caused by maternal Grave's disease.  Am J Perinatol. 1995;  12 240-242
  • 10 Watson W J, Fiegen M M. Fetal thyrotoxicosis associated with non-immune hydrops.  Am J Obstet Gynecol. 1995;  172 1039-1040
  • 11 Wallace C, Couch R, Ginsberg J. Fetal thyrotoxicosis: a case report and recommendations for prediction, diagnosis, and treatment.  Thyroid. 1995;  5 125-128
  • 12 Hatjis C G. Diagnosis and successful treatment of fetal goitrous hyperthyroidism caused by maternal Grave's disease.  Obstet Gynecol. 1993;  81 837-839
  • 13 Vali A, Wiles P, Thomas N B, Ludlam A. Relapse of maternal thyrotoxicosis presenting as a second-trimester fetal goiter.  Ultrasound Obstet Gynecol. 1993;  3 429-431
  • 14 Porreco R P, Bloch C A. Fetal blood sampling in the management of intrauterine thyrotoxicosis.  Obstet Gynecol. 1990;  76 509-512
  • 15 Wenstrom K D, Weiner C P, Williamson R A, Grant S S. Prenatal diagnosis of fetal hyperthyroidism using funipuncture.  Obstet Gynecol. 1990;  76 513-517
  • 16 Houck J A, Davis R E, Sharma H M. Thyroid-stimulating immunoglobulin as a cause of recurrent intrauterine fetal death.  Obstet Gynecol. 1988;  71 1018-1019
  • 17 Bruinse H W, Vermeulen-Meiners C, Wit J M. Fetal treatment for thyrotoxicosis in non-thyrotoxic pregnant women.  Fetal Ther. 1988;  3 152-157
  • 18 Page D V, Brady K, Mitchell J, Pehrson J, Wade G. The pathology of intrauterine thyrotoxicosis: two case reports.  Obstet Gynecol. 1988;  72 479-481
  • 19 Zakarija M, McKenzie J M, Hoffman W H. Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism.  J Clin Endocrinol Metab. 1986;  62 368-371
  • 20 Cove D H, Johnston P. Fetal hyperthyroidism: experience of treatment in four siblings.  Lancet. 1985;  1 430-432
  • 21 Pekonen F, Teramo K, Makinen T, Ikonen E, Osterlund K, Lamberg B A. Prenatal diagnosis and treatment of fetal thyrotoxicosis.  Am J Obstet Gynecol. 1984;  150 893-894
  • 22 Maxwell K D, Kearney K K, Johnson J WC, Eagan J W, Tyson J E. Fetal tachycardia associated with intrauterine fetal thyrotoxicosis.  Obstet Gynecol. 1980;  55 18S-22S
  • 23 Freeman R K, Garite T J, Nageotte M P. Basic pattern recognition. In: Fetal Heart Rate Monitoring. 3rd ed. Philadelphia; Lippincott Williams & Wilkins 2003: 63-89
  • 24 Fisher D A. Fetal thyroid function: diagnosis and management of fetal thyroid disorders.  Clin Obstet Gynecol. 1997;  40 16-31
  • 25 Belfar H L, Foley T P, Hill L M, Kislak S. Sonographic findings in maternal hyperthyroidism.  J Ultrasound Med. 1991;  10 281-284
  • 26 Check J H, Rezvani I, Goodner D, Hopper B. Prenatal treatment of thyrotoxicosis to prevent intrauterine growth retardation.  Obstet Gynecol. 1982;  60 122-124
  • 27 The American College of Obstetricians and Gynecologists .Antepartum Fetal Surveillance. Washington DC; The College 1999 Practice Bulletin No.: 9

Craig V TowersM.D. 

P.O. Box 8400

Huntington Beach, CA 92615

Email: drtowers@rbcpress.com

    >